Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: A retrospective study

Bulletin du Cancer

Volumn 98, Issue 9, 2011, Pages

  Asmane, Irène ^a   Kurtz, Jean Emmanuel ^a   Bajard, Agathe ^b   Guastalla, Jean Paul ^b   Meeus, Pierre ^b   Tredan, Olivier ^b   Galy, Intidhar Labidi ^b   Moullet, Isabelle ^c   Ardisson, Philippe ^c   Vincent, Lionel ^d   Coeffic, David ^e   Dufresne, Armelle ^f   Bergerat, Jean Pierre ^a   Ray Coquard, Isabelle ^b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Clinique de la Sauvegarde   (France)

^d Medical Oncology Unit   (France)

^e Groupe Hospitalier Mutualiste de Grenoble   (France)

^f CENTRE HOSPITALIER DE CHAMBÉRY   (France)

Author keywords

Bevacizumab; Gastro intestinal perforations; Microtubule targeting agents; Ovarian cancer

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; NAVELBINE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOODY DIARRHEA; CANCER PATIENT; CLINICAL ARTICLE; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG TOLERANCE; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; GINGIVORRHAGIA; HEMORRHAGIC PELVIC ABSCESS; HUMAN; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PELVIS ABSCESS; PROTEINURIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80053530589     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1436     Document Type: Article

References (40)

1. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005; 15 Suppl. 1 : 3-11. (Pubitemid 40696471)
2. Du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95 : 1320-9.
3. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002; 20 : 1161-3. (Pubitemid 34177419)
4. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15 Suppl 1 : 36-41. (Pubitemid 40696476)
5. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, Du Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 2010; 10 : 81-8.
6. Weber B, Lortholary A, Mayer F, et al. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 2009; 29 : 4195-200.
7. Parman MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventionnal platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361 : 2099-106.
8. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Clin Oncol 1991; 9 : 389-93.
9. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95 : 1-8. (Pubitemid 39286270)
10. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15 : 987-93. (Pubitemid 27106281)
11. Karabulut B, Sezgin C, Terek MC, et al. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy 2005; 51 : 347-51. (Pubitemid 41546711)
12. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25 : 2811-8. (Pubitemid 47123191)
13. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002; 20 : 2365-9. (Pubitemid 34441665)
14. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin Cancer Res 2004; 10 : 7439-49. (Pubitemid 39557505)
15. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74 : 1105-15. (Pubitemid 26184421)
16. Yoneda J, Kuniyasu H, Crispens MA, et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90 : 447-54. (Pubitemid 28160636)
17. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20 : 4368-80. (Pubitemid 35266299)
18. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77 : 527-43. (Pubitemid 29426311)
19. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005; 96 : 902-5. (Pubitemid 40255525)
20. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25 : 5165-71. (Pubitemid 350237599)
21. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25 : 5180-6. (Pubitemid 350232248)
22. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9 : 5721-8. (Pubitemid 37499496)
23. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59 : 3374-8. (Pubitemid 29334495)
24. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60 : 5565-70.
25. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161 : 1917-24. (Pubitemid 35265548)
26. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26 : 76-82.
27. O'Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 2008; 8 : 370-3.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 : 205-16.
29. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21(10 Suppl.) : 187s-93s.
30. Wright JD, Secord AA, Numnum TM, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18 : 400-6. (Pubitemid 351668295)
31. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007; 107 : 118-23. (Pubitemid 47464553)
32. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006; 102 : 134-9. (Pubitemid 44056263)
33. Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009; 115 : 396-400.
34. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007; 14 : 1860-9. (Pubitemid 46870935)
35. Hruban RH, Yardley JH, Donehower RC, Boitnott JK. Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 1989; 63 : 1944-50. (Pubitemid 19118894)
36. Seewaldt VL, Cain JM, Goff BA, Tamimi H, Greer B, Figge D. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 1997; 67 : 137-40. (Pubitemid 27500408)
37. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006; 107 : 83-9. (Pubitemid 43939034)
38. De Haan D, van den Berg M. Colonic perforation secondary to taxol therapy: an unusual presentation. Onkologie 2006; 29 : 541-2. (Pubitemid 44631678)
39. Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE4th, Straughn Jr. JM. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol 2009; 114 : 424-6.
40. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer: a Gynecologic Oncology Group study. J Clin Oncol 2010 ; 28 : 18s (suppl; abstr LBA1).